6 Conclusion
Our analysis of the FAERS database identified cardiac AEs for TKIs in a real-world setting. Our study found similar cardiovascular adverse effects with TKIs, Patients over 65 whose taking sorafenib, lenvatinib and regorafenib were at increased risk for developing cardiac AEs. These four TKIs were associated with increased risk of developing hypertension and cardiac failure. Furthermore, aortic dissection was a new complication with regorafenib. Use of lenvatinib may increase the risk of developing acute coronary syndrome and myocardial infarction. Clinicians should be aware of the various cardiac AEs associated with TKIs and the assessment of cardiovascular risk should be done before starting TKI treatments.